First author, year | Infection | Population | Model | Main outcome | Design outcome(s) | Remarks | ||
---|---|---|---|---|---|---|---|---|
Epidemiological category | Name | Type a | Structured/Network b | |||||
Atlas, 1993 [28] | Human, water-borne | Cryptosporidium | Volunteer subjects | Compartmental - deterministicc | No/No | Probability of infection | - Sample size | Exprimental study |
Lipsitch, 2001 [29] | Human, respiratory | Streptococcus pneumoniae | Not described | Compartmental - deterministic | No/No | Simple and conditional odds-ratios | - Timing of sampling | − |
Human, STI | HIV | Within-host (cells) | Compartmental - deterministic | No/No | HIV viral load change | - Timing of sampling - Frequency - Number - Sample size - Power | Statistical model used for fitting data | |
Clermont, 2004 [31] | Human, bacterial | Generic Gram-negative pathogen | Within-host (virtual infected patients) | Compartmental - deterministic | Yes/No | Identify people who will well respond to the anti-tumor necrosis factor | - Whom | − |
Hallett, 2008 [32] | Human, STI | HIV | Heterosexual population | Compartmental - deterministic | Yes/Yes | HIV incidence rate ratio | - Follow-up - Sample size - Power | − |
Dimitrov, 2013 [33] | Human, STI | HIV | Heterosexual population representative of sub-saharan Africa | Compartmental - deterministic | Yes/No | HIV incidence | - Sample size - Power | − |
Nishiura, 2013 [34] | Animal | influenza A viruses | Ferret in cages | Compartmental - stochastic | No/No | Number of pairs to include in 1-to-1 transmission studies | - Sample size - Power | − |
Human, STI | HIV | Adults, 18-44y, South Africa and Zambia | Compartmental - deterministic | Yes/Yes | HIV incidence | - Monitoring - Power | Effectively used to plan a three-arm cluster RCT | |
Cuadros, 2014 [36] | Human, STI | HIV | Serodiscordant couples; male population | IBM | No/Yes | HIV incidence | - Power | − |
Scott, 2014 [37] | Human, respiratory | Streptococcus pneumoniae | Infants | Compartmental - deterministic | Yes/No | Vaccine efficacy against acquisition and/or duration | - Follow-up - Timing of sampling - Monitoring | − |
Herzog, 2015 [38] | Human, STI | Chlamydia trachomatis | Women | Compartmental - deterministic | No/No | Pelvic inflammatory disease incidence | - Follow-up - Sample size - Power | − |